Thermo Fisher Scientific Inc.
NYSE:TMOMedical - Diagnostics & Research
+$4.45 today
- Market cap
- $256.67B
- Beta
- 0.87
- P/E (TTM)
- 25.3
- EPS (TTM)
- $18.44
- Dividend yield
- 0.39%
Volume 1.99M
Average 2.23M
TMO Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Thermo Fisher Scientific Inc.NYSE: TMO
Net Receivables · Q3 FY2026 · quarter ended Sep 2026
Net receivables falls 8.6% from a year ago
Net receivables stood at $9.63B at the end of Q3 FY2026, down 8.6% from a year earlier and up 1.8% from the prior quarter. Over 3 fiscal years it compounded at +3.9% a year.
Context
- Net receivables amounted to 8.4% of total assets at the end of Q3 FY2026, down 1.8 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -8.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 10.57B USD
- Year-over-year change
- +9.8%
- 4-year CAGR
- +4.3%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.57B | +9.8% |
| FY2024 | 2024-12-31 | 9.63B | -0.4% |
| FY2023 | 2023-12-31 | 9.66B | +2.5% |
| FY2022 | 2022-12-31 | 9.43B | +5.4% |
| FY2021 | 2021-12-31 | 8.95B | — |
Net Receivables vs competitors
How TMO compares with its peers on the latest reported figures
- TMO's Sep 2026 net receivables of $9.63B is the highest of the 10 companies compared; the peer median is $731.48M.
- Its year-over-year change of -8.6% is the lowest of 10, against a peer median of +7.3%.
- Net receivables amounts to 8.4% of total assets for TMO, versus a peer median of 8.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $9.63B | -8.6% | +3.9% | 8.4% | |
| Sep 2026 | $5.13B | +36.5% | -8.2% | 5.5% | |
| Jul 2026 | $1.99B | +172.2% | +4.7% | 8.0% | |
| Jul 2026 | $1.48B | +6.9% | +1.9% | 10.6% | |
| Jun 2026 | $875.4M | +18.5% | +7.3% | 14.5% | |
| Jun 2026 | $731.48M | +7.3% | +3.1% | 19.9% | |
| Jul 2026 | $709.18M | +7.3% | +6.7% | 5.9% | |
| Jun 2026 | $441.8M | -6.0% | -1.5% | 4.3% | |
| Jun 2026 | $399.05M | +3.4% | -2.5% | 6.8% | |
| Sep 2026 | $209.8M | +14.1% | +0.3% | 8.0% | |
| Peer median (excluding TMO) | $731.48M | +7.3% | +1.9% | 8.0% | |
Competitors are the stored peer set for TMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.48B | 8.52B | 8.08B | 4.02B | 9.85B |
| Short-term Investments | 0 | 0 | 0 | 1.56B | 253M |
| Net Receivables | 8.95B | 9.43B | 9.66B | 9.63B | 10.57B |
| Inventory | 5.05B | 5.63B | 5.09B | 4.98B | 5.43B |
| Other Current Assets | 1.64B | 1.64B | 1.76B | 1.95B | 2.61B |
| Total Current Assets | 20.11B | 25.23B | 24.59B | 22.14B | 28.71B |
| Property, Plant & Equipment (Net) | 9.86B | 10.87B | 11B | 10.8B | 10.57B |
| Goodwill | 41.92B | 41.2B | 44.02B | 45.85B | 49.36B |
| Intangible Assets | 20.15B | 17.48B | 16.67B | 15.53B | 15.84B |
| Long-term Investments | 73M | 155M | 59M | 560M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3B | 2.22B | 2.38B | 2.44B | 5.87B |
| Total Non-current Assets | 75.01B | 71.93B | 74.14B | 75.18B | 81.64B |
| Total Assets | 95.12B | 97.15B | 98.73B | 97.32B | 110.34B |
| Account Payables | 2.87B | 3.38B | 2.87B | 3.08B | 3.62B |
| Short-term Debt | 2.8B | 5.85B | 3.87B | 2.48B | 3.53B |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.66B | 2.6B | 2.69B | 2.85B | 2.71B |
| Other Current Liabilities | 2.68B | 3.08B | 2.98B | 2.94B | 0 |
| Total Current Liabilities | 13.44B | 17.01B | 14.01B | 13.33B | 15.19B |
| Long-term Debt | 32.15B | 28.91B | 31.31B | 29.06B | 35.85B |
| Deferred Tax Liabilities | 3.84B | 2.85B | 1.92B | 1.27B | 1.49B |
| Deferred Revenue (Non-current) | 1.24B | 1.18B | 1.5B | 1.14B | 0 |
| Other Non-current Liabilities | 2.1B | 1.75B | 1.9B | 1.61B | 4.27B |
| Total Non-current Liabilities | 40.71B | 36B | 37.87B | 34.32B | 41.62B |
| Total Liabilities | 54.15B | 53.01B | 51.88B | 47.65B | 56.81B |
| Common Stock | 439M | 441M | 442M | 444M | 445M |
| Retained Earnings | 35.43B | 41.91B | 47.36B | 53.1B | 59.16B |
| Accumulated OCI | (2.33B) | (3.1B) | (3.22B) | (2.7B) | (2.45B) |
| Other Stockholders Equity | 0 | 0 | 0 | (1M) | 0 |
| Minority Interest | 184M | 170M | 107M | 87M | 129M |
| Total Equity | 40.98B | 44.15B | 46.84B | 49.67B | 53.54B |
| Total Debt | 36.34B | 36.07B | 36.42B | 32.78B | 39.39B |
| Net Debt | 31.86B | 27.55B | 28.34B | 28.77B | 29.53B |
Thermo Fisher Scientific Inc.
NYSE:TMO
Intrinsic Alpha fair value
Locked
Current Price
$692.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.